Evidence map›Paper›PMID 42348164›Full record

SynthesisDiabetes, obesity & metabolism2026

Cardiovascular Efficacy of GLP-1 Receptor Agonists by Kidney Function: An Updated Meta-Analysis of Randomized Trials Including the SOUL Trial.

Masashi Hasebe, Chen-Yang Su, Daisuke Yabe, Satoshi Yoshiji

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Masashi HasebeCanada Excellence Research Chair Program in Genomic Medicine, McGill University, Montréal, Québec, Canada.ORCID https://orcid.org/0000-0001-7031-2446
Chen-Yang SuDepartment of Population Health Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID https://orcid.org/0000-0001-6071-4660
Daisuke YabeDepartment of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID https://orcid.org/0000-0002-5334-7687
Satoshi YoshijiCanada Excellence Research Chair Program in Genomic Medicine, McGill University, Montréal, Québec, Canada.ORCID https://orcid.org/0000-0001-8863-2413

Funding

Canada Research Chairs Program CRC-2025-00097CIHR 183596DNA to RNA Foundational ProgramJapan Society for the Promotion of ScienceMcGill University
6 · The paper itself

Abstract

aimsTo evaluate the cardiovascular efficacy and absolute benefit of glucagon-like peptide-1 receptor agonists (GLP-1RAs) by baseline estimated glomerular filtration rate (eGFR). MATERIALS AND

methodsPubMed and EMBASE were searched to 29 April 2026 for randomized placebo-controlled trials of GLP-1RAs in adults with type 2 diabetes or overweight/obesity that reported eGFR-stratified major adverse cardiovascular events (MACE). Hazard ratios (HRs) were extracted for eGFR < 60 and ≥ 60 mL/min/1.73 m

resultsNine publications from eight trials were included, comprising 70 822 participants; 70 534 had eGFR-stratified MACE data. GLP-1RAs similarly reduced MACE risk among participants with eGFR ≥ 60 and < 60 mL/min/1.73 m

conclusionsGLP-1RAs reduced MACE risk similarly across eGFR strata, while lower eGFR was associated with a larger estimated absolute cardiovascular benefit. These findings support GLP-1RA therapy in individuals with reduced kidney function.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsKidneyGlomerular Filtration RateHumansObesityRandomized Controlled Trials as TopicGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agentscardiovascular diseaseestimated glomerular filtration rateGLP‐1 receptor agonistskidney functionmeta‐analysis

Identifiers

PMID42348164
PMCPMC13449011

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.